losartan and Aging
losartan has been researched along with Aging in 75 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to examine the preventive effect of an ARB, losartan, against bladder dysfunction due to aging-related severe hypertension." | 8.12 | Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. ( Higashi, Y; Karashima, T; Kurabayashi, A; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2022) |
| "The fact that both E and L delayed cardiac hypertrophy/hyperplasia and aortic growth and raised aortic endothelium NOS activity indicates a protective effect on cardiovascular damage due to aging, exerted through inhibition of angiotensin II." | 7.71 | Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. ( Basso, N; González Bosc, LV; Kurnjek, ML; Müller, A; Terragno, NA, 2001) |
| "The consequences of aging for endothelium-dependent and endothelium-independent relaxations of rings from spontaneously hypertensive rats are ameliorated by losartan treatment, suggesting that angiotensin II plays a role via type 1 receptors." | 7.70 | Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998) |
| " In conclusion, (1) diminished EDHF availability accounts for the reduced Ach-relaxations produced by aging in MVB from SHR; (2) the enhancement of Ach-relaxations produced by losartan seems to be dependent on an increased NO availability; and (3) angiotensin II via angiotensin I type 1 receptor (AT1) plays an important role in the deleterious consequences of aging on endothelial function in SHR." | 7.70 | Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 7.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| " At the 48-week follow-up of the Evaluation of Losartan in the Elderly (ELITE) Study, the AT1 receptor antagonist losartan (at a dosage of 50 mg/day) was found to be superior to captopril 50 mg 3 times daily in terms of its effects on total mortality, total mortality and/or hospitalisation for CHF, and hospitalisation for any reason." | 6.40 | The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. ( Aronow, WS, 1998) |
| "Losartan treatment significantly improved several activity measurements during treatment period compared to placebo controlled group, including increased time on treadmill, traveling activity, standing activity, and decreased grid contacts (p-values<0." | 5.40 | Losartan improves measures of activity, inflammation, and oxidative stress in older mice. ( Abadir, P; Chuang, YF; Lin, CH; Roy, CN; Walston, JD; Xue, QL; Yang, H, 2014) |
| "Treatment with Losartan resulted in severe renal abnormalities." | 5.35 | Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. ( Ciuffo, GM; Forneris, ML; Fuentes, LB; Sánchez, SI; Seltzer, AM, 2008) |
| " We aimed to examine the preventive effect of an ARB, losartan, against bladder dysfunction due to aging-related severe hypertension." | 4.12 | Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. ( Higashi, Y; Karashima, T; Kurabayashi, A; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2022) |
| ", the aging model group, the high dose CH group, the middle dose CH group, the low dose CH group, the Losartan group, 17 in each group." | 3.81 | [Intervention Mechanism of Extracts from Radix Ginseng, Radix Notoginseng and Rhizoma Chuanxiong on Adventitia of Senescent Rats]. ( Lei, Y; Liu, JG; Wang, Y; Yang, J, 2015) |
| " Thus, the aim of this study was to compare the effects of losartan, angiotensin II type-1 receptor blocker, on systolic (SBP), diastolic (DBP), and mean (MBP) blood pressure, pulse pressure (PP) and heart rate as well as regional haemodynamics, cardiac hypertrophy and biochemical parameters in adult (L(9): 9-month-old) and aged (L(18): 18-month-old) spontaneously hypertensive rats (SHRs)." | 3.75 | Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats. ( Grujić-Milanović, J; Ivanov, M; Jovović, D; Mihailović-Stanojević, N; Miloradović, Z, 2009) |
| " This study was designed to determine the effects of aging and AT-1 receptor blockade (losartan 30 mg/kg/day beginning at 8 weeks of age) on NO system in this model." | 3.71 | Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. ( Kivlighn, S; Ni, ZN; Shahinfar, S; Vaziri, ND; Wang, XQ, 2002) |
| "The fact that both E and L delayed cardiac hypertrophy/hyperplasia and aortic growth and raised aortic endothelium NOS activity indicates a protective effect on cardiovascular damage due to aging, exerted through inhibition of angiotensin II." | 3.71 | Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. ( Basso, N; González Bosc, LV; Kurnjek, ML; Müller, A; Terragno, NA, 2001) |
| " Accordingly, ingestion of chromium and antioxidants which improve insulin sensitivity and/or lessen free radical formation could theoretically ameliorate these basic disorders and lessen signs and symptoms of chronic age-related disorders." | 3.71 | Long-term effects of chromium, grape seed extract, and zinc on various metabolic parameters of rats. ( Bagchi, D; Echard, B; Montamarry, S; Preuss, HG; Scheckenbach, R, 2001) |
| "The consequences of aging for endothelium-dependent and endothelium-independent relaxations of rings from spontaneously hypertensive rats are ameliorated by losartan treatment, suggesting that angiotensin II plays a role via type 1 receptors." | 3.70 | Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998) |
| " In conclusion, (1) diminished EDHF availability accounts for the reduced Ach-relaxations produced by aging in MVB from SHR; (2) the enhancement of Ach-relaxations produced by losartan seems to be dependent on an increased NO availability; and (3) angiotensin II via angiotensin I type 1 receptor (AT1) plays an important role in the deleterious consequences of aging on endothelial function in SHR." | 3.70 | Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 3.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| " This report emphasizes the importance of angiotensin II in vascular function alterations induced by aging in SHR." | 3.70 | Differential effects of losartan and doxazosin on vascular function in senescent spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1999) |
| "In studies of dementias and Alzheimer's disease (AD), some studies have shown that antihypertensive drugs, including angiotensin-converting enzyme inhibitors, have some moderate effects on cognitive decline, but that the angiotensin receptor antagonist losartan has a significantly beneficial effect." | 2.42 | Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. ( Gard, PR, 2004) |
| "Losartan was the first drug in this class to become commercially available." | 2.40 | Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. ( Burrell, LM; Johnston, CI, 1997) |
| " At the 48-week follow-up of the Evaluation of Losartan in the Elderly (ELITE) Study, the AT1 receptor antagonist losartan (at a dosage of 50 mg/day) was found to be superior to captopril 50 mg 3 times daily in terms of its effects on total mortality, total mortality and/or hospitalisation for CHF, and hospitalisation for any reason." | 2.40 | The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. ( Aronow, WS, 1998) |
| "Treatment with losartan (0." | 1.46 | miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. ( Adachi, H; Berkowitz, DE; Biswas, D; Das, S; Dunkerly-Eyring, B; Flavell, RA; Henao-Mejia, J; Hori, D; Nomura, Y; Santhanam, L; Steenbergen, C; Steppan, J, 2017) |
| "Losartan treatment significantly improved several activity measurements during treatment period compared to placebo controlled group, including increased time on treadmill, traveling activity, standing activity, and decreased grid contacts (p-values<0." | 1.40 | Losartan improves measures of activity, inflammation, and oxidative stress in older mice. ( Abadir, P; Chuang, YF; Lin, CH; Roy, CN; Walston, JD; Xue, QL; Yang, H, 2014) |
| "Treatment with losartan (15 mg/kg/day; n = 9) similarly mitigated signs of cardiac oxidative stress, but impairments in diastolic function persisted when compared with untreated rats (n = 7)." | 1.38 | Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats. ( Carter, CS; Groban, L; Kassik, KA; Lin, MS; Lindsey, S; Machado, FS; Wang, H, 2012) |
| "Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart." | 1.36 | Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010) |
| "Treatment with Losartan resulted in severe renal abnormalities." | 1.35 | Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. ( Ciuffo, GM; Forneris, ML; Fuentes, LB; Sánchez, SI; Seltzer, AM, 2008) |
| "Late losartan treatment had no effect on any of the parameters in either kidney, and PD-123319 had no effect on either kidney." | 1.34 | Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat. ( Burt, LE; Chevalier, RL; Coleman, CM; Forbes, MS; Minor, JJ; Thornhill, BA, 2007) |
| "Although cardiac hypertrophy in hypertension has been well recognized, the molecular mechanisms for the development of hypertrophy are still largely unknown." | 1.33 | Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. ( Chen, GQ; Chen, WL; Fang, NY; Jin, X; Liu, ZG; Shi, JZ; Wang, LS; Xia, L; Zhang, L; Zheng, Y, 2006) |
| "Captopril treatment partially reversed low insulin sensitivity in LSD rats, whereas losartan did not change it, which indicates that the effect of LSD on insulin sensitivity is angiotensin independent." | 1.31 | High- or low-salt diet from weaning to adulthood: effect on insulin sensitivity in Wistar rats. ( Dolnikoff, MS; Furukawa, LN; Heimann, JC; Machado, UF; Okamoto, MM; Prada, P, 2000) |
| "Body weights were 10% lower in the LO group at the start but remained unchanged relative to the CO group during the entire 8-day period of observation." | 1.31 | AT(1) receptor blockade with losartan during gestation in Wistar rats leads to an increase in thirst and sodium appetite in their adult female offspring. ( Butler, DG; Midgely, A; Nemati, B; Pak, SH, 2002) |
Research
Studies (75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (32.00) | 18.2507 |
| 2000's | 33 (44.00) | 29.6817 |
| 2010's | 14 (18.67) | 24.3611 |
| 2020's | 4 (5.33) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| van Thiel, BS | 1 |
| van der Linden, J | 1 |
| Ridwan, Y | 1 |
| Garrelds, IM | 1 |
| Vermeij, M | 1 |
| Clahsen-van Groningen, MC | 1 |
| Qadri, F | 1 |
| Alenina, N | 1 |
| Bader, M | 1 |
| Roks, AJM | 1 |
| Danser, AHJ | 1 |
| Essers, J | 1 |
| van der Pluijm, I | 1 |
| Shimizu, S | 1 |
| Nagao, Y | 1 |
| Kurabayashi, A | 1 |
| Shimizu, T | 1 |
| Higashi, Y | 1 |
| Karashima, T | 1 |
| Saito, M | 1 |
| Qureshi, AW | 1 |
| Altamimy, R | 1 |
| El Habhab, A | 1 |
| El Itawi, H | 1 |
| Farooq, MA | 1 |
| Zobairi, F | 1 |
| Hasan, H | 1 |
| Amoura, L | 1 |
| Kassem, M | 1 |
| Auger, C | 1 |
| Schini-Kerth, V | 1 |
| Toti, F | 1 |
| Wang, Y | 4 |
| Cong, R | 1 |
| Tian, Y | 1 |
| Chen, C | 1 |
| Zhang, Q | 1 |
| Zhou, X | 1 |
| Ji, C | 1 |
| Meng, X | 1 |
| Song, N | 1 |
| Hori, D | 1 |
| Dunkerly-Eyring, B | 1 |
| Nomura, Y | 1 |
| Biswas, D | 1 |
| Steppan, J | 1 |
| Henao-Mejia, J | 1 |
| Adachi, H | 1 |
| Santhanam, L | 1 |
| Berkowitz, DE | 1 |
| Steenbergen, C | 1 |
| Flavell, RA | 1 |
| Das, S | 1 |
| Hamatani, H | 1 |
| Eng, DG | 1 |
| Kaverina, NV | 1 |
| Gross, KW | 1 |
| Freedman, BS | 1 |
| Pippin, JW | 1 |
| Shankland, SJ | 1 |
| Tao, H | 1 |
| Rui, C | 1 |
| Zheng, J | 1 |
| Tang, J | 1 |
| Wu, L | 1 |
| Shi, A | 1 |
| Chen, N | 1 |
| He, R | 1 |
| Wu, C | 1 |
| Li, J | 1 |
| Yin, X | 1 |
| Zhang, P | 1 |
| Zhu, Z | 1 |
| Tao, J | 1 |
| Xiao, J | 1 |
| Mao, C | 1 |
| Xu, Z | 1 |
| Lin, CH | 1 |
| Yang, H | 1 |
| Xue, QL | 1 |
| Chuang, YF | 1 |
| Roy, CN | 1 |
| Abadir, P | 1 |
| Walston, JD | 2 |
| Lei, Y | 1 |
| Yang, J | 1 |
| Liu, JG | 1 |
| Costa, G | 1 |
| Garabito, M | 1 |
| Jiménez-Altayó, F | 1 |
| Onetti, Y | 1 |
| Sabate, M | 1 |
| Vila, E | 1 |
| Dantas, AP | 1 |
| Ognibene, DT | 1 |
| Oliveira, PR | 1 |
| Marins de Carvalho, LC | 1 |
| Costa, CA | 1 |
| Espinoza, LA | 1 |
| Criddle, DN | 1 |
| Tano, T | 1 |
| Soares de Moura, R | 1 |
| Resende, AC | 1 |
| Senador, D | 1 |
| Kanakamedala, K | 1 |
| Irigoyen, MC | 1 |
| Morris, M | 1 |
| Elased, KM | 1 |
| Chan, EC | 1 |
| Jones, GT | 1 |
| Dusting, GJ | 1 |
| Datla, SR | 1 |
| Jiang, F | 1 |
| Inserra, F | 3 |
| Basso, N | 4 |
| Ferder, M | 1 |
| Userpater, M | 1 |
| Stella, I | 2 |
| Paglia, N | 1 |
| Inserra, P | 1 |
| Tenembaum, D | 1 |
| Ferder, L | 3 |
| Mihailović-Stanojević, N | 1 |
| Miloradović, Z | 1 |
| Grujić-Milanović, J | 1 |
| Ivanov, M | 1 |
| Jovović, D | 1 |
| Sumbalová, Z | 1 |
| Kucharská, J | 1 |
| Kristek, F | 1 |
| Stein, M | 1 |
| Boulaksil, M | 1 |
| Jansen, JA | 1 |
| Herold, E | 1 |
| Noorman, M | 1 |
| Joles, JA | 1 |
| van Veen, TA | 1 |
| Houtman, MJ | 1 |
| Engelen, MA | 1 |
| Hauer, RN | 1 |
| de Bakker, JM | 1 |
| van Rijen, HV | 1 |
| Hobara, N | 2 |
| Goda, M | 2 |
| Hashikawa, N | 1 |
| Jin, X | 2 |
| Zamami, Y | 1 |
| Takatori, S | 1 |
| Kawasaki, H | 2 |
| Carter, CS | 3 |
| Giovannini, S | 1 |
| Giovaninni, S | 1 |
| Seo, DO | 1 |
| DuPree, J | 1 |
| Morgan, D | 1 |
| Chung, HY | 2 |
| Lees, H | 1 |
| Daniels, M | 1 |
| Hubbard, GB | 1 |
| Lee, S | 1 |
| Ikeno, Y | 1 |
| Foster, TC | 1 |
| Buford, TW | 1 |
| Marzetti, E | 1 |
| Kim, JM | 1 |
| Heo, HS | 1 |
| Choi, YJ | 1 |
| Ye, BH | 1 |
| Mi Ha, Y | 1 |
| Seo, AY | 1 |
| Yu, BP | 1 |
| Leeuwenburgh, C | 1 |
| Groban, L | 1 |
| Lindsey, S | 1 |
| Wang, H | 1 |
| Lin, MS | 1 |
| Kassik, KA | 1 |
| Machado, FS | 1 |
| Abadir, PM | 1 |
| Foster, DB | 1 |
| Crow, M | 1 |
| Cooke, CA | 1 |
| Rucker, JJ | 1 |
| Jain, A | 1 |
| Smith, BJ | 1 |
| Burks, TN | 1 |
| Cohn, RD | 1 |
| Fedarko, NS | 1 |
| Carey, RM | 2 |
| O'Rourke, B | 1 |
| Sanchis-Gomar, F | 1 |
| Gómez-Cabrera, MC | 1 |
| Viña, J | 1 |
| Zhou, XJ | 1 |
| Vaziri, ND | 2 |
| Zhang, J | 2 |
| Wang, HW | 1 |
| Wang, XQ | 2 |
| Ni, ZN | 1 |
| Kivlighn, S | 1 |
| Shahinfar, S | 1 |
| Tedesco, MA | 1 |
| Ratti, G | 1 |
| Di Salvo, G | 1 |
| Natale, F | 1 |
| de Cavanagh, EM | 1 |
| Piotrkowski, B | 1 |
| Fraga, CG | 1 |
| Gard, PR | 1 |
| Stegbauer, J | 1 |
| Vonend, O | 1 |
| Oberhauser, V | 1 |
| Sellin, L | 1 |
| Rump, LC | 1 |
| Gessei-Tsutsumi, N | 1 |
| Takayama, F | 1 |
| Akiyama, S | 1 |
| Kurosaki, Y | 1 |
| Wang, M | 1 |
| Spinetti, G | 1 |
| Jiang, LQ | 1 |
| Monticone, R | 1 |
| Zhao, D | 1 |
| Cheng, L | 1 |
| Krawczyk, M | 1 |
| Talan, M | 1 |
| Pintus, G | 1 |
| Lakatta, EG | 1 |
| Demirci, B | 1 |
| McKeown, PP | 1 |
| Bayraktutan, U | 1 |
| Tuttle, JB | 1 |
| Hannan, JL | 1 |
| Smallegange, C | 1 |
| Hale, TM | 1 |
| Heaton, JP | 1 |
| Adams, MA | 1 |
| Xia, L | 1 |
| Wang, LS | 1 |
| Shi, JZ | 1 |
| Zheng, Y | 1 |
| Chen, WL | 1 |
| Zhang, L | 1 |
| Liu, ZG | 1 |
| Chen, GQ | 1 |
| Fang, NY | 1 |
| Yanes, LL | 1 |
| Romero, DG | 1 |
| Iles, JW | 1 |
| Iliescu, R | 1 |
| Gomez-Sanchez, C | 1 |
| Reckelhoff, JF | 1 |
| McGrath, JC | 1 |
| Baumann, M | 2 |
| Janssen, BJ | 1 |
| Hermans, JJ | 1 |
| Peutz-Kootstra, C | 1 |
| Witzke, O | 1 |
| Smits, JF | 2 |
| Struijker Boudier, HA | 1 |
| Coleman, CM | 1 |
| Minor, JJ | 1 |
| Burt, LE | 1 |
| Thornhill, BA | 1 |
| Forbes, MS | 1 |
| Chevalier, RL | 2 |
| Palmieri, V | 1 |
| Pini, R | 1 |
| Chiara Cavallini, M | 1 |
| Cini, R | 1 |
| Pietrelli, A | 1 |
| Terragno, NA | 2 |
| Bartholome, R | 1 |
| Peutz-Kootstra, CJ | 1 |
| Struijker-Boudier, HA | 1 |
| Lee, JH | 1 |
| Xia, S | 1 |
| Ragolia, L | 1 |
| Sánchez, SI | 1 |
| Seltzer, AM | 1 |
| Fuentes, LB | 1 |
| Forneris, ML | 1 |
| Ciuffo, GM | 1 |
| Nishimura, N | 1 |
| Takase, H | 1 |
| Morita, T | 1 |
| Fornes, P | 1 |
| Richer, C | 1 |
| Vacher, E | 1 |
| Bruneval, P | 1 |
| Giudicelli, JF | 1 |
| Cai, G | 1 |
| Gurdal, H | 1 |
| Seasholtz, TM | 1 |
| Johnson, MD | 1 |
| Ruzicka, M | 1 |
| Keeley, FW | 1 |
| Leenen, FH | 1 |
| Tufro-McReddie, A | 2 |
| Johns, DW | 1 |
| Geary, KM | 1 |
| Dagli, H | 1 |
| Everett, AD | 1 |
| Gomez, RA | 2 |
| Tank, JE | 1 |
| Vora, JP | 1 |
| Houghton, DC | 1 |
| Anderson, S | 1 |
| Díaz-Torga, GS | 1 |
| Becú-Villalobos, D | 1 |
| Libertun, C | 1 |
| Baylis, C | 1 |
| Pitt, B | 2 |
| Chang, P | 1 |
| Timmermans, PB | 1 |
| Breault, L | 1 |
| Lehoux, JG | 1 |
| Gallo-Payet, N | 1 |
| Burrell, LM | 1 |
| Johnston, CI | 1 |
| Sil, P | 1 |
| Sen, S | 1 |
| Carvalho, CR | 1 |
| Thirone, AC | 1 |
| Gontijo, JA | 1 |
| Velloso, LA | 1 |
| Saad, MJ | 1 |
| Nakano, N | 1 |
| Moriguchi, A | 1 |
| Morishita, R | 1 |
| Kida, I | 1 |
| Tomita, N | 1 |
| Matsumoto, K | 1 |
| Nakamura, T | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Aronow, WS | 1 |
| Maeso, R | 3 |
| Rodrigo, E | 3 |
| Muñoz-García, R | 2 |
| Navarro-Cid, J | 3 |
| Ruilope, LM | 3 |
| Cachofeiro, V | 3 |
| Lahera, V | 3 |
| Conlin, PR | 1 |
| Elkins, M | 1 |
| Liss, C | 1 |
| Vrecenak, AJ | 1 |
| Barr, E | 1 |
| Edelman, JM | 1 |
| Yoneda, H | 1 |
| Toriumi, W | 1 |
| Ohmachi, Y | 1 |
| Okumura, F | 1 |
| Fujimura, H | 1 |
| Nishiyama, S | 1 |
| Touyz, RM | 1 |
| Endemann, D | 1 |
| He, G | 1 |
| Li, JS | 1 |
| Schiffrin, EL | 1 |
| Nowicki, PT | 1 |
| Minnich, LA | 1 |
| Prada, P | 1 |
| Okamoto, MM | 1 |
| Furukawa, LN | 1 |
| Machado, UF | 1 |
| Heimann, JC | 1 |
| Dolnikoff, MS | 1 |
| Ma, LJ | 1 |
| Nakamura, S | 1 |
| Whitsitt, JS | 1 |
| Marcantoni, C | 1 |
| Davidson, JM | 1 |
| Fogo, AB | 1 |
| González Bosc, LV | 1 |
| Kurnjek, ML | 1 |
| Müller, A | 1 |
| Preuss, HG | 1 |
| Montamarry, S | 1 |
| Echard, B | 1 |
| Scheckenbach, R | 1 |
| Bagchi, D | 1 |
| Butler, DG | 1 |
| Pak, SH | 1 |
| Midgely, A | 1 |
| Nemati, B | 1 |
| Rajagopalan, S | 1 |
| Brook, R | 1 |
| Mehta, RH | 1 |
| Supiano, M | 1 |
| Kubo, T | 1 |
| Ibusuki, T | 1 |
| Chiba, S | 1 |
| Kambe, T | 1 |
| Fukumori, R | 1 |
| Arrizurieta, EE | 1 |
| Brocca, S | 1 |
| Tsutsumi, K | 1 |
| Saavedra, JM | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Muscle Strength Maintenance in Older Adults[NCT01989793] | Phase 2 | 37 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Losartan and ET-1 Mediated Constriction in Postmenopausal Women With High Blood Pressure[NCT03371823] | Phase 4 | 8 participants (Actual) | Interventional | 2017-09-01 | Terminated (stopped due to We experienced challenges recruiting unmedicated women with high blood pressure for the intervention.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change From Baseline in Isokinetic Strength
"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 16 (i.e., baseline minus week 16) was the outcome of the analysis. A negative number indicates decrease in strength from week 0 to week 16." (NCT01989793)
Timeframe: Baseline to Week 16
| Intervention | Newton (Mean) |
|---|---|
| Losartan | -7.40 |
| Placebo | -4.27 |
Change From Baseline in Isokinetic Strength
"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 24 (i.e., baseline minus week 24) was the outcome of the analysis. A negative number indicates a decrease in strength from week 0 to week 24." (NCT01989793)
Timeframe: Baseline to Week 24
| Intervention | Newton (Mean) |
|---|---|
| Losartan | -9.20 |
| Placebo | -7.00 |
Change From Baseline in Isokinetic Strength
"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 8 (i.e., baseline minus week 8) was the outcome of the analysis. A negative number indicates that there was a decrease in isokinetic strength from week 0 to week 8." (NCT01989793)
Timeframe: Baseline to Week 8
| Intervention | Newton (Mean) |
|---|---|
| Losartan | -4.90 |
| Placebo | -4.73 |
Fatiguability
"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to that of the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 16
| Intervention | percentage of work (Mean) |
|---|---|
| Losartan | 16.51 |
| Placebo | 8.77 |
Fatiguability
"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to that of the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 24
| Intervention | percentage of work (Mean) |
|---|---|
| Losartan | 17.07 |
| Placebo | 9.05 |
Fatiguability
"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to the total work in the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 8
| Intervention | percentage of work (Mean) |
|---|---|
| Losartan | 14.29 |
| Placebo | 7.87 |
Number of Participants Experiencing Any Amount of Decrease in Frailty
Number of participants experiencing any amount of decrease in frailty score from baseline to Week 16 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 3 |
| Placebo | 5 |
Number of Participants Experiencing Any Amount of Decrease in Frailty
Number of participants experiencing any amount of decrease in frailty score from baseline to Week 24 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 3 |
| Placebo | 5 |
Number of Participants Experiencing Any Amount of Decrease in Frailty
Number of participants experiencing any amount of decrease in frailty score from baseline to Week 8 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 3 |
| Placebo | 6 |
ET-1 Mediated Constriction
Cutaneous blood flow is measured via laser Doppler flowmetry during cutaneous microdialysis perfusions of ET-A and ET-B receptor antagonists as previously described by Wenner MM in 2017(see reference list). (NCT03371823)
Timeframe: Each participant was assessed at baseline and 2 weeks later.
| Intervention | % change blood flow flux (Mean) | |
|---|---|---|
| ETA blockade | ETB blockade | |
| Normotensive | 437 | 42 |
Reviews
6 reviews available for losartan and Aging
| Article | Year |
|---|---|
[Role of angiontensin receptors in remodeling perivascular nerves].
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; C | 2010 |
Does the angiotensin II receptor antagonist losartan improve cognitive function?
Topics: Aged; Aged, 80 and over; Aging; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2002 |
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.
Topics: Aging; Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2004 |
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 1995 |
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 1997 |
The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study.
Topics: Aged; Aging; Angiotensin Receptor Antagonists; Antihypertensive Agents; Evaluation Studies as Topic; | 1998 |
Trials
3 trials available for losartan and Aging
| Article | Year |
|---|---|
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 1995 |
A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension.
Topics: Aged; Aging; Antihypertensive Agents; Calcium Channel Blockers; Diastole; Double-Blind Method; Drug | 1998 |
Effect of losartan in aging-related endothelial impairment.
Topics: Aged; Aged, 80 and over; Aging; Blood Pressure; Brachial Artery; Cell Adhesion Molecules; Chemokine | 2002 |
Other Studies
67 other studies available for losartan and Aging
| Article | Year |
|---|---|
In Vivo Renin Activity Imaging in the Kidney of Progeroid
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; DNA | 2021 |
Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats.
Topics: Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2022 |
Ageing enhances the shedding of splenocyte microvesicles with endothelial pro-senescent effect that is prevented by a short-term intake of omega-3 PUFA EPA:DHA 6:1.
Topics: Aging; Animals; Antihypertensive Agents; Biomarkers; Cell-Derived Microparticles; Cells, Cultured; C | 2020 |
Restoration of erectile function by suppression of corporal apoptosis and oxidative stress with losartan in aged rats with erectile dysfunction.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Erectile Dysfunction; Losartan; Male; Oxida | 2020 |
miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling.
Topics: Aging; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiovascular Disea | 2017 |
Lineage tracing aged mouse kidneys shows lower number of cells of renin lineage and reduced responsiveness to RAAS inhibition.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2018 |
Angiotensin II-mediated vascular changes in aged offspring rats exposed to perinatal nicotine.
Topics: Acetylcholine; Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdom | 2013 |
Losartan improves measures of activity, inflammation, and oxidative stress in older mice.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Catalase; Disease | 2014 |
[Intervention Mechanism of Extracts from Radix Ginseng, Radix Notoginseng and Rhizoma Chuanxiong on Adventitia of Senescent Rats].
Topics: Adventitia; Aging; Angiotensin II; Animals; Aorta, Thoracic; Drugs, Chinese Herbal; Losartan; Panax; | 2015 |
Sex differences in angiotensin II responses contribute to a differential regulation of cox-mediated vascular dysfunction during aging.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclooxygenase 2; Endotheli | 2016 |
Angiotensin II-mediated vasodilation is reduced in adult spontaneously hypertensive rats despite enhanced expression of AT2 receptors.
Topics: Acetylcholine; Aging; Angiotensin II; Animals; Blotting, Western; Bradykinin; Gene Expression Regula | 2009 |
Cardiovascular and autonomic phenotype of db/db diabetic mice.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System; B | 2009 |
Prevention of aortic elastic lamina defects by losartan in apolipoprotein(E)-deficient mouse.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseas | 2009 |
Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system.
Topics: Actins; Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2009 |
Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Cardiomegaly; | 2009 |
Losartan improved respiratory function and coenzyme Q content in brain mitochondria of young spontaneously hypertensive rats.
Topics: Aging; alpha-Tocopherol; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Brain; Cell | 2010 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr | 2010 |
Differential effects of enalapril and losartan on body composition and indices of muscle quality in aged male Fischer 344 × Brown Norway rats.
Topics: Adiposity; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal | 2011 |
Inhibition of NF-κB-induced inflammatory responses by angiotensin II antagonists in aged rat kidney.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibi | 2011 |
Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats.
Topics: Aging; Analysis of Variance; Animals; Arterial Pressure; Diastole; Disease Models, Animal; Dose-Resp | 2012 |
Identification and characterization of a functional mitochondrial angiotensin system.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Autocrine Communication; Cell Line; Chronic | 2011 |
The loss of muscle mass and sarcopenia: non hormonal intervention.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates | 2011 |
Association of renal injury with nitric oxide deficiency in aged SHR: prevention by hypertension control with AT1 blockade.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterioles; Hypertension, | 2002 |
Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pr | 2002 |
Enalapril and losartan attenuate mitochondrial dysfunction in aged rats.
Topics: Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Res | 2003 |
Angiotensin II receptor modulation of renal vascular resistance and neurotransmission in young and adult spontaneously hypertensive rats.
Topics: Aging; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Imidazoles; Kidney; Losartan | 2005 |
Long-term inhibition of angiotensin prevents reduction of periarterial innervation of calcitonin gene-related peptide (CGRP)-containing nerves in spontaneously hypertensive rats.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; C | 2005 |
Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats.
Topics: Adrenergic alpha-Agonists; Aging; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; | 2005 |
Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; B | 2005 |
Blockade of angiotensin II and aging: is the spontaneously hypertensive rat a suitable model?
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseases; Cardiovascular Sys | 2006 |
Impact of antihypertensive treatments on erectile responses in aging spontaneously hypertensive rats.
Topics: Aging; Animals; Antihypertensive Agents; Apomorphine; Blood Pressure; Enalapril; Hydralazine; Hydroc | 2006 |
Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats.
Topics: Age Factors; Aging; Algorithms; Animals; Antihypertensive Agents; Blotting, Western; Cardiomegaly; D | 2006 |
Sexual dimorphism in the renin-angiotensin system in aging spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Aging; Angiotensins; Animals; Antihypertensive Agents; Female; Kidney; | 2006 |
Simply removing pressure doesn't work, but youthful drug-taking prevents hereditary mid-life failure.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood | 2007 |
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin | 2007 |
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brach | 2007 |
Protective effect of long-term angiotensin II inhibition.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibi | 2007 |
Sustained tubulo-interstitial protection in SHRs by transient losartan treatment: an effect of decelerated aging?
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Cycle; Cell Division; Hyperplasia; Hyp | 2008 |
Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats.
Topics: Aging; Angiotensin II; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Endothelium, Vas | 2008 |
Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney.
Topics: Abnormalities, Drug-Induced; Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiote | 2008 |
[Effects of chronic losartan treatment on myocardial, vascular structure and reactivity with aging in spontaneously hypertensive rats (SHR): its effects compared with those of captopril].
Topics: Aging; Animals; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Captopril; Coronary C | 1995 |
Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood | 1993 |
Age-related changes in angiotensin II-stimulated vascular contraction and inositol phosphate accumulation in Fischer 344 rats.
Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Arteries; Bipheny | 1994 |
The renin-angiotensin system and volume overload-induced changes in cardiac collagen and elastin.
Topics: Aging; Animals; Biphenyl Compounds; Blood Pressure; Collagen; Coronary Circulation; Elastin; Enalapr | 1994 |
Angiotensin II type 1 receptor: role in renal growth and gene expression during normal development.
Topics: Aging; Animals; Animals, Newborn; Biphenyl Compounds; Blood Pressure; Gene Expression; Imidazoles; K | 1994 |
Altered renal vascular responses in the aging rat kidney.
Topics: Aging; Angiotensin II; Animals; Arginine; Biphenyl Compounds; Blood Pressure; Endothelins; Glomerula | 1994 |
Ontogeny of angiotensin-II-induced prolactin release in vivo and in vitro in female and male rats.
Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Dose-Response | 1994 |
Renal responses to acute angiotensin II inhibition and administered angiotensin II in the aging, conscious, chronically catheterized rat.
Topics: Age Factors; Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Comp | 1993 |
Angiotensin II receptors in the human adrenal gland.
Topics: Adrenal Glands; Adult; Aging; Angiotensin II; Angiotensin Receptor Antagonists; Autoradiography; Bin | 1996 |
Angiotensin II and myocyte growth: role of fibroblasts.
Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Biphenyl Compoun | 1997 |
Effect of captopril, losartan, and bradykinin on early steps of insulin action.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Captopril; Ins | 1997 |
Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats.
Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; A | 1997 |
Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats.
Topics: Aging; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Hypertension; Losartan; Male; Rats; | 1998 |
Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR.
Topics: Acetylcholine; Aging; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Dose-Respons | 1998 |
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1998 |
Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR.
Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Hypertension; Imid | 1999 |
Effects of systemic hypotension on postnatal intestinal circulation: role of angiotensin.
Topics: Aging; Angiotensin II; Animals; Animals, Newborn; Hemodynamics; Hypotension; In Vitro Techniques; In | 1999 |
Differential effects of losartan and doxazosin on vascular function in senescent spontaneously hypertensive rats.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Aging; Angiotensin II; Animals; Antihypertensive Agents | 1999 |
High- or low-salt diet from weaning to adulthood: effect on insulin sensitivity in Wistar rats.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biological Transp | 2000 |
Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.
Topics: Aging; Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihypertensive Agents; Aorta, Thor | 2000 |
Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; A | 2001 |
Long-term effects of chromium, grape seed extract, and zinc on various metabolic parameters of rats.
Topics: Aging; Animals; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Body Weight; Chrom | 2001 |
AT(1) receptor blockade with losartan during gestation in Wistar rats leads to an increase in thirst and sodium appetite in their adult female offspring.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Appetite; Blood Pressure; Body Weight; Carotid Art | 2002 |
Altered mitogen-activated protein kinase activation in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Aging; Animals; Aorta, Thoracic; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activatio | 2002 |
Dietary protein modulates intrarenal distribution of renin and its mRNA during development.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Biphenyl Compounds; Body Weight; | 1992 |
Differential development of angiotensin II receptor subtypes in the rat brain.
Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Brain; Im | 1991 |